

TRADEMARK ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Credit Suisse AG		01/31/2011	bank: SWITZERLAND
RECEIVING PARTY DATA			
Name:	King Pharmaceuticals, Inc.		
Street Address:	501 Fifth Street		
City:	Bristol		
State/Country:	TENNESSEE		
Postal Code:	37620		
Entity Type:	CORPORATION: TENNESSEE		
PROPERTY NUMBERS Total: 19			
Property Type	Number	Word Mark	
Registration Number:	2865269	BICILLIN	
Registration Number:	2925042	BICILLIN	
Registration Number:	2954783	DROP DOSE	
Registration Number:	3396250		
Registration Number:	2893097	KING	
Registration Number:	2927077	KING	
Registration Number:	2927079	KING PHARMACEUTICALS	
Registration Number:	2871392	KING PHARMACEUTICALS	
Registration Number:	3589117	K KING PHARMACEUTICALS	
Registration Number:	2927078	KING PHARMACEUTICALS	
Registration Number:	2874243	KING PHARMACEUTICALS	
Registration Number:	2656254	KINGKARE	
Registration Number:	1912168	LORABID	
Registration Number:	2031644	MONARCH PHARMACEUTICALS	

CH \$490.00 2865269

900182912

TRADEMARK
REEL: 004465 FRAME: 0691

Registration Number:	0578347	TAPAZOLE
Registration Number:	0684353	TIGAN
Registration Number:	1259079	TILADE
Serial Number:	77309098	CORVUE
Serial Number:	77767185	CORVUE

CORRESPONDENCE DATA

Fax Number: (202)778-5299

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 202.662.5299

Email: trademarks@cov.com

Correspondent Name: Kathleen T. Gallagher-Duff, Esq.

Address Line 1: 1201 Pennsylvania Avenue, N.W.

Address Line 4: Washington, DISTRICT OF COLUMBIA 20004

ATTORNEY DOCKET NUMBER:	029459.00030
NAME OF SUBMITTER:	Cheryl L. Fountain/Paralegal Specialist
Signature:	/cheryllfountain/
Date:	02/02/2011

Total Attachments: 3

source=King Pharmaceuticals TM Release#page1.tif

source=King Pharmaceuticals TM Release#page2.tif

source=King Pharmaceuticals TM Release#page3.tif

Release of Security Interest in Trademarks

January 31, 2011

WHEREAS, KING PHARMACEUTICALS, INC., a Tennessee corporation, as Borrower (the “**Assignee**”), certain of its subsidiaries, as Guarantors, and CREDIT SUISSE AG (“**Credit Suisse**”), in its capacity as Collateral Agent for the Secured Parties (as each term is defined in the GCA (as defined below)), entered into that certain Guarantee and Collateral Agreement (the “**GCA**”) dated as of May 11, 2010;

WHEREAS, pursuant to the GCA, Credit Suisse and the Assignee entered into that certain Trademark Security Agreement dated May 11, 2010 and recorded with the United States Patent and Trademark Office on May 12, 2010 on Reel No. 4204, Frame No. 0777 (the “**Trademark Security Agreement**”);

WHEREAS, under the Trademark Security Agreement, the Assignee granted to Credit Suisse a security interest in certain Trademark Collateral (as defined in the Trademark Security Agreement), including those items set forth on Schedule 1 hereto (collectively, the “**Released Trademark Collateral**”);

WHEREAS, the parties agree and acknowledge that the foregoing United States Patent and Trademark Office assignment record may list Credit Suisse AG in a capacity other than Collateral Agent, and that the security interest was granted to, and this release is correctly made by, Credit Suisse, as Collateral Agent; and

WHEREAS, Credit Suisse desires to release the security interest granted by the Assignee under the Trademark Security Agreement in the Released Trademark Collateral.


NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Credit Suisse, as Collateral Agent for the Secured Parties, does hereby unconditionally, irrevocably and absolutely terminate, release, extinguish and forever discharge the security interest granted under the Trademark Security Agreement in the Released Trademark Collateral, together with all of the goodwill of the business connected with the use of, or symbolized by, such Released Trademark Collateral, and hereby unconditionally, irrevocably and absolutely assigns, transfers and conveys to the Assignee all right, title and interest of Credit Suisse in, to and under such Released Trademark Collateral and such goodwill granted under the Trademark Security Agreement. This Release of Security Interest in Trademarks shall be binding upon Credit Suisse’s legal representatives, assigns and successors, and upon the Secured Parties and their legal representatives, assigns and successors. Credit Suisse also hereby authorizes, and requests, the Director of the United States Patent and Trademark Office or his delegate to record this Release of Security Interest in Trademarks against the Released Trademark Collateral.

[signature page to follow]

IN WITNESS WHEREOF, Credit Suisse has caused this Release of Security Interest in Trademarks to be duly executed by its officers thereunto duly authorized as of the day and year first above written.

CREDIT SUISSE AG, CAYMAN
ISLANDS BRANCH

By: 
Name: DOREEN BARR
Title: DIRECTOR

By: 
Name: VIPUL DHADDA
Title: ASSOCIATE

[signature page – King Pharmaceuticals, Inc. trademark release]

Schedule 1

KING PHARMACEUTICALS, INC.

U.S. TRADEMARK REGISTRATIONS

Trademark	Registration No.	Registration Date
BICILLIN	2865269	July 20, 2004
BICILLIN (Stylized)	2925042	February 8, 2005
DROP DOSE	2954783	May 24, 2005
K Logo and Design	3396250	March 11, 2008
KING and Crown Design	2893097	October 12, 2004
KING and Crown Design	2927077	February 22, 2005
KING PHARMACEUTICALS	2927079	February 22, 2005
KING PHARMACEUTICALS	2871392	August 10, 2004
King Pharmaceuticals and K Design	3589117	March 10, 2009
KING PHARMACEUTICALS within Crown Design	2927078	February 22, 2005
KING PHARMACEUTICALS within Crown Design	2874243	August 17, 2004
KINGKARE	2656254	December 3, 2002
LORABID	1912168	August 15, 1995
MONARCH PHARMACEUTICALS and Design	2031644	January 21, 1997
TAPAZOLE	578347	August 4, 1953
TIGAN	684353	September 1, 1959
TILADE	1259079	November 29, 1983

U.S. TRADEMARK APPLICATIONS

Trademark	Application No.	Application Date
CORVUE	77/309098	October 19, 2007
CORVUE and Design	77/767,185	June 24, 2009

TRADEMARK LICENSES

Name of Agreement	Parties (Licensor/Licensee)	Date of Agreement	Subject Matter
Purchase Agreement	Ligand Pharmaceuticals Incorporated/ King Pharmaceuticals, Inc and King Pharmaceuticals Research and Development, Inc.	September 6, 2006	Avinza
Product Acquisition and License Agreement	Aventis Pharma S.A./ King Pharmaceuticals	December 30, 2002	Synercid